Literature DB >> 28444193

Quantitative assessment of timing, efficiency, specificity and genetic mosaicism of CRISPR/Cas9-mediated gene editing of hemoglobin beta gene in rhesus monkey embryos.

Uros Midic1, Pei-Hsuan Hung2, Kailey A Vincent1, Benjamin Goheen1, Patrick G Schupp3, Diane D Chen3, Daniel E Bauer3,4,5, Catherine A VandeVoort2, Keith E Latham1.   

Abstract

Gene editing technologies offer new options for developing novel biomedical research models and for gene and stem cell based therapies. However, applications in many species demand high efficiencies, specificity, and a thorough understanding of likely editing outcomes. To date, overall efficiencies, rates of off-targeting and degree of genetic mosaicism have not been well-characterized for most species, limiting our ability to optimize methods. As a model gene for measuring these parameters of the CRISPR/Cas9 application in a primate species (rhesus monkey), we selected the β-hemoglobin gene (HBB), which also has high relevance to the potential application of gene editing and stem-cell technologies for treating human disease. Our data demonstrate an ability to achieve a high efficiency of gene editing in rhesus monkey zygotes, with no detected off-target effects at selected off-target loci. Considerable genetic mosaicism and variation in the fraction of embryonic cells bearing targeted alleles are observed, and the timing of editing events is revealed using a new model. The uses of Cas9-WT protein combined with optimized concentrations of sgRNAs are two likely areas for further refinement to enhance efficiency while limiting unfavorable outcomes that can be exceedingly costly for application of gene editing in primate species.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28444193      PMCID: PMC5886216          DOI: 10.1093/hmg/ddx154

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  25 in total

Review 1.  Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.

Authors:  Megan D Hoban; Stuart H Orkin; Daniel E Bauer
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

2.  Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Authors:  F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

3.  Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing.

Authors:  Xiangjin Kang; Wenyin He; Yuling Huang; Qian Yu; Yaoyong Chen; Xingcheng Gao; Xiaofang Sun; Yong Fan
Journal:  J Assist Reprod Genet       Date:  2016-04-06       Impact factor: 3.412

4.  One-step generation of p53 gene biallelic mutant Cynomolgus monkey via the CRISPR/Cas system.

Authors:  Haifeng Wan; Chunjing Feng; Fei Teng; Shihua Yang; Baoyang Hu; Yuyu Niu; Andy Peng Xiang; Weizhen Fang; Weizhi Ji; Wei Li; Xiaoyang Zhao; Qi Zhou
Journal:  Cell Res       Date:  2014-11-28       Impact factor: 25.617

5.  Primate preimplantation embryo is a target for relaxin during early pregnancy.

Authors:  Catherine A Vandevoort; Namdori R Mtango; Keith E Latham; Dennis R Stewart
Journal:  Fertil Steril       Date:  2011-06-08       Impact factor: 7.329

6.  Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA.

Authors:  Xiquan Liang; Jason Potter; Shantanu Kumar; Namritha Ravinder; Jonathan D Chesnut
Journal:  J Biotechnol       Date:  2016-11-11       Impact factor: 3.307

7.  Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos.

Authors:  Yuyu Niu; Bin Shen; Yiqiang Cui; Yongchang Chen; Jianying Wang; Lei Wang; Yu Kang; Xiaoyang Zhao; Wei Si; Wei Li; Andy Peng Xiang; Jiankui Zhou; Xuejiang Guo; Ye Bi; Chenyang Si; Bian Hu; Guoying Dong; Hong Wang; Zuomin Zhou; Tianqing Li; Tao Tan; Xiuqiong Pu; Fang Wang; Shaohui Ji; Qi Zhou; Xingxu Huang; Weizhi Ji; Jiahao Sha
Journal:  Cell       Date:  2014-01-30       Impact factor: 41.582

8.  Feasibility for a large scale mouse mutagenesis by injecting CRISPR/Cas plasmid into zygotes.

Authors:  Daisuke Mashiko; Samantha A M Young; Masanaga Muto; Hirotaka Kato; Kaori Nozawa; Masaki Ogawa; Taichi Noda; Yeon-Joo Kim; Yuhkoh Satouh; Yoshitaka Fujihara; Masahito Ikawa
Journal:  Dev Growth Differ       Date:  2013-12-26       Impact factor: 2.053

9.  Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos.

Authors:  Zhuchi Tu; Weili Yang; Sen Yan; An Yin; Jinquan Gao; Xudong Liu; Yinghui Zheng; Jiezhao Zheng; Zhujun Li; Su Yang; Shihua Li; Xiangyu Guo; Xiao-Jiang Li
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

10.  Efficient gene targeting in mouse zygotes mediated by CRISPR/Cas9-protein.

Authors:  Chris J Jung; Junli Zhang; Elizabeth Trenchard; Kent C Lloyd; David B West; Barry Rosen; Pieter J de Jong
Journal:  Transgenic Res       Date:  2016-11-30       Impact factor: 2.788

View more
  11 in total

1.  Mosaicism diminishes the value of pre-implantation embryo biopsies for detecting CRISPR/Cas9 induced mutations in sheep.

Authors:  Marcela Vilarino; Fabian Patrik Suchy; Sheikh Tamir Rashid; Helen Lindsay; Juan Reyes; Bret Roberts McNabb; Talitha van der Meulen; Mark O Huising; Hiromitsu Nakauchi; Pablo Juan Ross
Journal:  Transgenic Res       Date:  2018-10-03       Impact factor: 2.788

Review 2.  Modeling genetic diseases in nonhuman primates through embryonic and germline modification: Considerations and challenges.

Authors:  Jenna K Schmidt; Kathryn M Jones; Trevor Van Vleck; Marina E Emborg
Journal:  Sci Transl Med       Date:  2022-03-02       Impact factor: 19.319

Review 3.  The dawn of non-human primate models for neurodevelopmental disorders.

Authors:  Tomomi Aida; Guoping Feng
Journal:  Curr Opin Genet Dev       Date:  2020-07-18       Impact factor: 5.578

4.  Deriving rabbit embryonic stem cells by small molecule inhibitors.

Authors:  Jiao Liu; Xiumei Zhu; Jinshan Li; Zhihui Liu; Yanhong Liu; Fei Xue; Lan Yang; Liyou An; Chien-Hong Chen; Giorgio Antonio Presicce; Qiping Zheng; Fuliang Du
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

Review 5.  Non-human primates as a model for human development.

Authors:  Tomonori Nakamura; Kohei Fujiwara; Mitinori Saitou; Tomoyuki Tsukiyama
Journal:  Stem Cell Reports       Date:  2021-05-11       Impact factor: 7.765

6.  Identification of on-target mutagenesis during correction of a beta-thalassemia splice mutation in iPS cells with optimised CRISPR/Cas9-double nickase reveals potential safety concerns.

Authors:  Suad Alateeq; Dmitry Ovchinnikov; Timothy Tracey; Deanne Whitworth; Abdullah Al-Rubaish; Amein Al-Ali; Ernst Wolvetang
Journal:  APL Bioeng       Date:  2018-12-03

Review 7.  CRISPR/Cas9-mediated genome editing in nonhuman primates.

Authors:  Yu Kang; Chu Chu; Fang Wang; Yuyu Niu
Journal:  Dis Model Mech       Date:  2019-10-16       Impact factor: 5.758

Review 8.  Gene editing monkeys: Retrospect and outlook.

Authors:  Weizheng Liang; Junli He; Chenyu Mao; Chengwei Yu; Qingxue Meng; Jun Xue; Xueliang Wu; Shanliang Li; Yukai Wang; Hongyang Yi
Journal:  Front Cell Dev Biol       Date:  2022-09-08

Review 9.  CRISPR/Cas9 genome editing to create nonhuman primate models for studying stem cell therapies for HIV infection.

Authors:  Jenna Kropp Schmidt; Matthew R Reynolds; Thaddeus G Golos; Igor I Slukvin
Journal:  Retrovirology       Date:  2022-08-10       Impact factor: 3.768

10.  Genome editing of CCR5 by CRISPR-Cas9 in Mauritian cynomolgus macaque embryos.

Authors:  Jenna Kropp Schmidt; Nick Strelchenko; Mi Ae Park; Yun Hee Kim; Katherine D Mean; Michele L Schotzko; Hyun Jun Kang; Thaddeus G Golos; Igor I Slukvin
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.